Werewolf Therapeutics, Inc. HOWL
We take great care to ensure that the data presented and summarized in this overview for Werewolf Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HOWL
View all-
Ra Capital Management, L.P. Boston, MA6.68MShares$6.28 Million0.23% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.31MShares$4.05 Million19.47% of portfolio
-
Bio Impact Capital LLC Cambridge, MA2.41MShares$2.26 Million0.88% of portfolio
-
Bank Of America Corp Charlotte, NC1.83MShares$1.72 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.59MShares$1.49 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.41MShares$1.32 Million0.0% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L3627KShares$589,2010.33% of portfolio
-
Dc Funds, LP Mclean, VA589KShares$553,75526.46% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny456KShares$428,6400.0% of portfolio
-
Pfm Health Sciences, LP San Francisco, CA401KShares$377,0430.07% of portfolio
Latest Institutional Activity in HOWL
Top Purchases
Top Sells
About HOWL
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at HOWL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 12
2026
|
Luke Evnin |
SELL
Open market or private sale
|
Indirect |
58,980
-2.49%
|
$0
$0.57 P/Share
|
|
Jan 09
2026
|
Luke Evnin |
SELL
Open market or private sale
|
Indirect |
24,678
-1.03%
|
$0
$0.61 P/Share
|
|
Jan 08
2026
|
Luke Evnin |
SELL
Open market or private sale
|
Indirect |
7,716
-0.32%
|
$0
$0.63 P/Share
|
|
Jan 07
2026
|
Luke Evnin |
SELL
Open market or private sale
|
Indirect |
11,915
-0.49%
|
$0
$0.64 P/Share
|
|
Jan 06
2026
|
Luke Evnin |
SELL
Open market or private sale
|
Indirect |
40,761
-1.66%
|
$0
$0.65 P/Share
|
|
Jan 05
2026
|
Luke Evnin |
SELL
Open market or private sale
|
Indirect |
18,378
-0.74%
|
$0
$0.64 P/Share
|
|
Jan 02
2026
|
Luke Evnin |
SELL
Open market or private sale
|
Indirect |
18,568
-0.75%
|
$0
$0.63 P/Share
|
|
Dec 31
2025
|
Luke Evnin |
SELL
Open market or private sale
|
Indirect |
24,962
-0.99%
|
$0
$0.62 P/Share
|
|
Dec 30
2025
|
Luke Evnin |
SELL
Open market or private sale
|
Indirect |
34,847
-1.37%
|
$0
$0.61 P/Share
|
|
Dec 29
2025
|
Luke Evnin |
SELL
Open market or private sale
|
Indirect |
108,606
-4.08%
|
$0
$0.61 P/Share
|
|
Dec 26
2025
|
Luke Evnin |
SELL
Open market or private sale
|
Indirect |
35,632
-1.32%
|
$0
$0.63 P/Share
|
|
Dec 24
2025
|
Luke Evnin |
SELL
Open market or private sale
|
Indirect |
16,310
-0.6%
|
$0
$0.65 P/Share
|
|
Dec 23
2025
|
Luke Evnin |
SELL
Open market or private sale
|
Indirect |
71,428
-2.57%
|
$0
$0.63 P/Share
|
|
Dec 22
2025
|
Luke Evnin |
SELL
Open market or private sale
|
Indirect |
59,307
-2.09%
|
$0
$0.69 P/Share
|
|
Dec 17
2025
|
Luke Evnin |
SELL
Open market or private sale
|
Indirect |
9,983
-0.35%
|
$9,983
$1.14 P/Share
|
|
Dec 16
2025
|
Luke Evnin |
SELL
Open market or private sale
|
Indirect |
14,548
-0.51%
|
$14,548
$1.05 P/Share
|
|
Dec 15
2025
|
Luke Evnin |
SELL
Open market or private sale
|
Indirect |
23,640
-0.82%
|
$23,640
$1.07 P/Share
|
|
Dec 12
2025
|
Luke Evnin |
SELL
Open market or private sale
|
Indirect |
17,858
-0.61%
|
$17,858
$1.08 P/Share
|
|
Dec 11
2025
|
Luke Evnin |
SELL
Open market or private sale
|
Indirect |
28,009
-0.95%
|
$28,009
$1.07 P/Share
|
|
Dec 10
2025
|
Luke Evnin |
SELL
Open market or private sale
|
Indirect |
37,104
-1.25%
|
$37,104
$1.06 P/Share
|
Last 12 Months Summary
| Exercise of in-the-money or at-the-money derivatives securities | 102K shares |
|---|---|
| Open market or private purchase | 536K shares |
| Open market or private sale | 5.88M shares |
|---|